Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
02 08 2023
02 08 2023
Historique:
medline:
3
8
2023
pubmed:
13
6
2023
entrez:
13
6
2023
Statut:
ppublish
Résumé
Patients with haematological malignancies (HM) are at high risk of developing invasive fungal disease (IFD) with high morbidity and attributable mortality. We reviewed data published until September 2021 to update the 2017 antifungal prophylaxis recommendations of the German Society of Haematology and Medical Oncology (DGHO). The strong recommendation to administer antifungal prophylaxis in patients with HM with long-lasting neutropenia, i.e. <500 cells/μL for >7 days remains unchanged. Posaconazole remains the drug of choice for mould-active prophylaxis in these patients. Novel treatment options in HM, such as CAR-T-cell treatment or novel targeted therapies for acute myeloid leukaemia (AML) were considered, however, data are insufficient to give general recommendations for routine antifungal prophylaxis in these patients. Major changes regarding specific recommendations compared to the 2017 edition are the now moderate instead of mild support for the recommendations of isavuconazole and voriconazole. Furthermore, published evidence on micafungin allows recommending it at moderate strength for its use in HM. For the first time we included recommendations for non-pharmaceutical measures regarding IFD, comprising the use of high-efficiency particulate air (HEPA) filters, smoking, measures during construction work and neutropenic diets. We reviewed the impact of antifungal prophylaxis with triazoles on drug-drug interactions with novel targeted therapies that are metabolized via cytochrome p450 where triazoles inhibit CYP3A4/5. The working group recommends reducing the dose of venetoclax when used concomitantly with strong CYP3A4 inhibiting antifungals. Furthermore, we reviewed data on the prophylactic use of novel antifungal agents. Currently there is no evidence to support their use in a prophylactic setting in clinical practice.
Identifiants
pubmed: 37311136
pii: 7197251
doi: 10.1093/jac/dkad143
pmc: PMC10393896
doi:
Substances chimiques
Antifungal Agents
0
Cytochrome P-450 CYP3A
EC 1.14.14.1
Triazoles
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1813-1826Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Références
J Fungi (Basel). 2021 Feb 23;7(2):
pubmed: 33672208
J Fungi (Basel). 2021 Jul 23;7(8):
pubmed: 34436127
Cochrane Database Syst Rev. 2014 Sep 04;(9):CD002033
pubmed: 25188770
Lancet Infect Dis. 2021 Aug;21(8):e246-e257
pubmed: 33606997
J Oncol Pharm Pract. 2019 Mar;25(2):398-403
pubmed: 30319061
BMC Infect Dis. 2018 Apr 2;18(1):155
pubmed: 29609553
J Antimicrob Chemother. 2019 Oct 1;74(10):3049-3055
pubmed: 31360992
J Oncol Pharm Pract. 2018 Jan;24(1):63-66
pubmed: 27824587
J Oncol Pharm Pract. 2020 Jun;26(4):873-881
pubmed: 31566111
Transpl Infect Dis. 2021 Aug;23(4):e13587
pubmed: 33590676
Int J Antimicrob Agents. 2017 Feb;49(2):218-223
pubmed: 27989379
Ann Hematol. 2018 Feb;97(2):197-207
pubmed: 29218389
J Infect. 2016 Nov;73(5):496-505
pubmed: 27394404
Rev Infect Dis. 1987 Jan-Feb;9 Suppl 1:S94-9
pubmed: 3027853
Cancer J. 2022 Jan-Feb 01;28(1):2-13
pubmed: 35072368
Antibiotics (Basel). 2021 Apr 23;10(5):
pubmed: 33922419
J Oncol Pharm Pract. 2016 Apr;22(2):228-34
pubmed: 25471252
J Chemother. 2019 Nov - Dec;31(7-8):401-407
pubmed: 31359851
Expert Opin Drug Metab Toxicol. 2020 Jul;16(7):539-550
pubmed: 32478597
J Antimicrob Chemother. 2016 Jun;71(6):1747
pubmed: 26960721
Cochrane Database Syst Rev. 2015 Jun 29;(6):CD005341
pubmed: 26118415
N Engl J Med. 2007 Jan 25;356(4):348-59
pubmed: 17251531
Bone Marrow Transplant. 1998 Jun;21(12):1231-8
pubmed: 9674857
J Clin Oncol. 2003 Dec 15;21(24):4615-26
pubmed: 14673051
Clin Infect Dis. 2020 Feb 14;70(5):723-730
pubmed: 30958538
Open Forum Infect Dis. 2021 Mar 08;8(7):ofab113
pubmed: 34337090
Antimicrob Agents Chemother. 2018 Jun 26;62(7):
pubmed: 29735569
BMJ Support Palliat Care. 2019 Dec;9(4):425-433
pubmed: 30948447
Antimicrob Agents Chemother. 2009 Feb;53(2):703-7
pubmed: 19029316
Ann Hematol. 2014 Sep;93(9):1449-56
pubmed: 24951122
Medicine (Baltimore). 2021 May 21;100(20):e25448
pubmed: 34011022
Med Mal Infect. 2016 Jun;46(4):226-9
pubmed: 27126350
Ann Oncol. 2006 Aug;17(8):1306-12
pubmed: 16766594
Blood Rev. 2017 Mar;31(2):17-29
pubmed: 27682882
Mycoses. 2020 Oct;63(10):1021-1032
pubmed: 32744334
Ann Oncol. 2009 Sep;20(9):1560-1564
pubmed: 19451183
J Clin Oncol. 2021 Oct 10;39(29):3261-3272
pubmed: 34156898
Leuk Res. 2017 Jun;57:1-8
pubmed: 28231491
Clin Microbiol Rev. 2021 Dec 15;34(4):e0031120
pubmed: 34190571
Br J Haematol. 2005 Jul;130(2):265-70
pubmed: 16029455
Clin Infect Dis. 2021 Aug 2;73(3):416-426
pubmed: 32463873
Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38
pubmed: 29544767
Clin Infect Dis. 2008 May 1;46(9):1401-8
pubmed: 18419443
N Engl J Med. 2007 Jan 25;356(4):335-47
pubmed: 17251530
J Infect. 2018 Sep;77(3):227-234
pubmed: 29746955
J Mycol Med. 2018 Jun;28(2):379-383
pubmed: 29673771
Mycoses. 1989;32 Suppl 1:103-8
pubmed: 2561181
Biol Blood Marrow Transplant. 2020 Jun;26(6):1195-1202
pubmed: 32088367
J Antimicrob Chemother. 2017 Oct 1;72(10):2902-2905
pubmed: 29091205
Clin Infect Dis. 2020 Jul 27;71(3):672-676
pubmed: 31756246
Antimicrob Agents Chemother. 2012 May;56(5):2652-8
pubmed: 22290953
Mycoses. 2019 Aug;62(8):698-705
pubmed: 31145490
J Gastrointest Surg. 2020 Apr;24(4):832-840
pubmed: 31066013
Lancet Haematol. 2021 Dec;8(12):e922-e933
pubmed: 34687602
J Infect Chemother. 2017 Jun;23(6):360-367
pubmed: 28341518
J Fungi (Basel). 2020 Dec 21;6(4):
pubmed: 33371513
J Antimicrob Chemother. 2017 Dec 01;72(12):3406-3413
pubmed: 28961714
Ann Hematol. 2021 Feb;100(2):321-336
pubmed: 33079221
J Microbiol Immunol Infect. 2019 Dec;52(6):973-982
pubmed: 30322746
Pharmacol Res Perspect. 2021 Feb;9(1):e00690
pubmed: 33340279
Oral Dis. 2021 Oct;27(7):1631-1643
pubmed: 32762108
Ther Drug Monit. 2018 Feb;40(1):115-119
pubmed: 29189664
Curr Opin Infect Dis. 2020 Dec;33(6):449-457
pubmed: 33009139
J Hosp Infect. 2017 Aug;96(4):336-341
pubmed: 28545828
Mycoses. 2021 Apr;64(4):437-444
pubmed: 33354800
J Antimicrob Chemother. 2017 Dec 01;72(12):3414-3419
pubmed: 28961894
Rev Esp Quimioter. 2020 Apr;33(2):110-115
pubmed: 32056418
J Antimicrob Chemother. 2017 Dec 1;72(12):3501
pubmed: 29029280
Ann Hematol. 2021 Jun;100(6):1603-1620
pubmed: 33846857
Ann Hematol. 2016 Sep;95(9):1435-55
pubmed: 27339055
Eur J Haematol. 2020 Apr;104(4):291-298
pubmed: 31856310
Turk J Haematol. 2016 Mar 5;33(1):41-7
pubmed: 26376622
Drugs. 2021 Oct;81(15):1703-1729
pubmed: 34626339
Haematologica. 2015 Feb;100(2):284-92
pubmed: 25638805
J Infect. 2019 Aug;79(2):167-173
pubmed: 31233810
PLoS One. 2018 Jun 8;13(6):e0197851
pubmed: 29883443
Clin Infect Dis. 2021 May 18;72(10):1755-1763
pubmed: 32236406
Mycoses. 2020 Sep;63(9):900-910
pubmed: 32531854
Antimicrob Agents Chemother. 2015 Apr;59(4):2078-85
pubmed: 25624327
Pharmaceutics. 2021 Nov 19;13(11):
pubmed: 34834376
Lancet Oncol. 2019 Jul;20(7):984-997
pubmed: 31175001
Int J Clin Oncol. 2019 Nov;24(11):1449-1458
pubmed: 31300904
J Antimicrob Chemother. 2022 Aug 25;77(9):2500-2505
pubmed: 35726095
Clin Pharmacol Ther. 2020 Mar;107(3):563-570
pubmed: 31549389
Clin Microbiol Infect. 2020 Nov;26(11):1481-1487
pubmed: 32535150
Clin Infect Dis. 2021 Dec 6;73(11):e3647-e3655
pubmed: 32955088
Haematologica. 2009 Jan;94(1):113-22
pubmed: 19066334
Med Mycol. 2021 Oct 04;59(10):970-979
pubmed: 34036319
Cancer. 2021 Jul 15;127(14):2489-2499
pubmed: 33793970
Cancer Chemother Pharmacol. 2022 Jul;90(1):19-27
pubmed: 35751657
Ann Hematol. 2015 Apr;94(4):547-56
pubmed: 25697592
Eur J Cancer. 2021 Sep;155:281-290
pubmed: 34399112
J Antimicrob Chemother. 2019 Aug 1;74(8):2341-2346
pubmed: 31119272
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5483-91
pubmed: 27381396
Int J Antimicrob Agents. 2017 Sep;50(3):384-388
pubmed: 28694233
Curr Opin Infect Dis. 2021 Aug 1;34(4):297-306
pubmed: 34039878
Eur J Haematol. 2018 Feb;100(2):140-146
pubmed: 29105850
Br J Haematol. 2011 Nov;155(3):318-27
pubmed: 21880032
JAMA. 2019 Nov 5;322(17):1673-1681
pubmed: 31688884
J Pediatric Infect Dis Soc. 2021 Apr 30;10(4):417-425
pubmed: 33136159
J Antimicrob Chemother. 2016 Mar;71(3):718-26
pubmed: 26612870
Clin Pharmacol Ther. 2010 Jul;88(1):115-9
pubmed: 20505665
Int J Antimicrob Agents. 2015 Jul;46(1):82-7
pubmed: 25956843
Mycopathologia. 2015 Jun;179(5-6):337-45
pubmed: 25637199
Mycoses. 2020 Dec;63(12):1373-1381
pubmed: 32885534
J Antimicrob Chemother. 2017 Mar 1;72(suppl_1):i12-i18
pubmed: 28355463
Clin Ther. 2017 Feb;39(2):359-367
pubmed: 28161120
Med Mycol. 2021 Jan 4;59(1):93-101
pubmed: 32898264
Int J Antimicrob Agents. 2020 Mar;55(3):105886
pubmed: 31926286
Leuk Res. 2021 Sep;108:106610
pubmed: 34048999
Antimicrob Agents Chemother. 2019 Sep 23;63(10):
pubmed: 31358587
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5595-9
pubmed: 27324763
Clin Microbiol Infect. 2014 Apr;20 Suppl 3:1-4
pubmed: 24606200
Antimicrob Agents Chemother. 2015 Nov 02;60(1):376-86
pubmed: 26525782
J Clin Oncol. 2008 Dec 10;26(35):5684-8
pubmed: 18955453
Lancet. 2016 Feb 20;387(10020):760-9
pubmed: 26684607
Mycoses. 2018 Mar;61(3):206-212
pubmed: 29125660
Ann Oncol. 2016 Oct;27(10):1916-22
pubmed: 27456299
Lancet Haematol. 2022 May;9(5):e361-e373
pubmed: 35483397
BMC Infect Dis. 2019 Jan 9;19(1):38
pubmed: 30626352
Pharmacotherapy. 2007 Dec;27(12):1627-36
pubmed: 18041883
J Antimicrob Chemother. 2017 Aug 1;72(8):2359-2367
pubmed: 28575414
Antimicrob Agents Chemother. 2018 Sep 24;62(10):
pubmed: 30012757